We provide you with 20 years of free, institutional-grade data for AVXL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AVXL. Explore the full financial landscape of AVXL stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| MISSLING CHRISTOPHER U | Sale | -268,000 | $7.98 | $2,139,310 | 2023-06-30 |
| MISSLING CHRISTOPHER U | Derivatives Exercise | 500,000 | 2023-06-30 | ||
| Skarpelos Athanasios | Sale | -50,000 | $9.06 | $453,000 | 2022-05-27 |
| Skarpelos Athanasios | Derivatives Exercise | 50,000 | 2022-05-27 | ||
| Boenisch Sandra | Sale | -166,696 | $26.53 | $4,422,445 | 2021-07-01 |
| Boenisch Sandra | Derivatives Exercise | 166,696 | 2021-07-01 | ||
| MISSLING CHRISTOPHER U | Sale | -51,620 | $26 | $1,342,120 | 2021-07-01 |
| MISSLING CHRISTOPHER U | Derivatives Exercise | 51,620 | 2021-07-01 | ||
| FAVUS ELLIOT | Sale | -145,000 | $11.7 | $1,696,283 | 2021-05-25 |
| FAVUS ELLIOT | Derivatives Exercise | 145,000 | 2021-05-25 | ||
| Donhauser Peter D.O. | Open Market Purchase | 1,000 | $10.93 | 2021-05-19 | |
| FAVUS ELLIOT | Sale | -145,500 | $12.66 | $1,841,855 | 2021-02-26 |
| FAVUS ELLIOT | Derivatives Exercise | 145,500 | 2021-02-26 | ||
| Donhauser Peter D.O. | Open Market Purchase | 1,165 | $12.62 | 2021-02-23 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 1,360 | $2.92 | 2018-03-09 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 1,450 | $2.73 | 2018-03-07 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 1,500 | $2.63 | 2018-03-06 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 1,650 | $2.41 | 2018-03-05 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.39 | 2017-10-26 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.92 | 2017-10-24 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.49 | 2017-10-19 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.27 | 2017-10-18 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 750 | $4.22 | 2017-10-16 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.3 | 2017-10-05 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.2 | 2017-10-02 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.21 | 2017-09-29 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $3.88 | 2017-09-26 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.23 | 2017-09-20 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.4 | 2017-09-19 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.58 | 2017-09-14 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.81 | 2017-09-11 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.76 | 2017-09-08 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.9 | 2017-09-05 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.48 | 2017-08-31 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.44 | 2017-08-29 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.54 | 2017-08-25 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $4.07 | 2017-08-21 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $3.81 | 2017-08-18 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 375 | $3.7 | 2017-08-14 | |
| MISSLING CHRISTOPHER U | Open Market Purchase | 750 | $3.55 | 2017-08-11 |
The information provided in this report about AVXL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Anavex Life Sciences Corp(NASDAQ:AVXL) 
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Pha...
Website: http://www.anavex.com
Founded: 2004
Full Time Employees: 16
Sector: Healthcare
Industry: Biotechnology